01869 238000

BOOK A TOUR

Exit Right 2023 Series

July 17th 2023

Exit Right 2023 is a free expert-led, must-attend event series for any entrepreneur looking to drive their business from start-up to exit.

Following on from the successful 2022 Exit Right events, this year’s talks are from founders and directors who have successfully exited their businesses as well as M&A experts.

Founders will tell you first hand about their exit journey – what went well and what didn’t go quite so well. You will find out the best strategies to employ and what it takes to be one of the successful 10% of businesses that exit – whether it’s through an acquisition or IPO.

There are lots of factors to consider when deciding whether to grow or sell your business. Many entrepreneurs share their experiences of successful growth strategies and tips for acquisitions and business exit.

 

Please click on the link to view the videos.

March 12th 2024

Oxford StemTech From Start-Up to Expansion at Heyford park Innovation Centre

We are thrilled that Oxford StemTech, a start-up based at Heyford Park Innovation Centre are graduating to larger premises due to recent growth and business success. The journey of Oxford StemTech began with the vision of its founders, Zameel Cader, Galbha Duggal and Satyan Chintawar, who embarked on their entrepreneurial […]

January 25th 2024

New Customers Albion Rye Associates join HPIC

Life Sciences recruitment partners for the UK and International markets. Established in 2018, Albion Rye Associates LTD are the go-to recruitment partner for Healthcare Consultancies, Pharmaceutical, and Biotechnology clients globally, through merging over half a century of recruiting experience with sector-specific knowledge and expertise. We are excited to announce the […]

November 21st 2023

ConserV Bioscience grows team of vaccine specialists

ConserV Bioscience Ltd specialises in the development of vaccines against human diseases. The company was created in October 2020 as a spin out of the parent company PepTcell, so they have just celebrated their third anniversary. They have a large portfolio of vaccine candidates in different stages of development. Their […]